Press "Enter" to skip to content

Beta Cell Regeneration; Essure’s Afterlife; T2D and Erectile Dysfunction

Researchers at Mount Sinai discovered a combination of two drug classes that yielded the highest proliferation rate of human beta cells. This “makes beta cells regenerate at rates that are suitable for treatment. The next big hurdle is figuring out how to deliver them directly to the pancreas,” said lead author Andrew Stewart, MD. Click here for a video on these findings. (Cell Metabolism)

FDA Commissioner Scott Gottlieb, MD, laid out the agency’s plan to monitor Bayer’s permanent birth control device Essure following its final removal from the U.S. market in 10 days.

Genetic study suggests a causal relationship between type 2 diabetes and erectile dysfunction “through hypothalamic dysregulation.” (American Journal of Human Genetics)

A higher percentage of women with metabolic syndrome experienced a complication during pregnancy compared with women who didn’t have MetS. (PLOS Medicine)

The American Diabetes Association released their 2019 Standards of Medical Care in Diabetes.

The European Medicines Agency granted Orphan Medicinal Product designation to an investigational ready-to-use glucagon for the treatment of non-insulinoma pancreatogenous hypoglycemia syndrome, Xeris Pharmaceuticals announced.

Less than a year after bariatric surgery, the average amount of liver fat dropped back to a normal range for people with obesity. (Radiology)

Another SGLT-2 inhibitor called LX2761 demonstrated safety and tolerability in newly released phase I data, said Lexicon Pharmaceuticals.

A new oral treatment for anemia caused by chronic kidney disease, roxadustat, was approved in China this week — the first country to approve the drug — said developer AstraZeneca. The first-in-class drug inhibits hypoxia-inducible prolyl hydroxylase to therefore promote erythropoietin release and downregulate hepcidin.


last updated